Search

A 29-year-old man experienced myocarditis and perimyocarditis after receiving the tozinameran (Pfizer BioNTech COVID-19) vaccine. The man had a history of previous perimyocarditis episodes and had been taking colchicine and metoprolol succinate for the past 21 months. He presented to the emergency room with abdominal pain, cramps, and diarrhea, and developed severe pericardial pain similar to his previous episodes. He was treated with colchicine and ibuprofen, and imaging showed multiple pericardial areas of late gadolinium enhancement. He was discharged in improved condition and received his second vaccine dose four weeks later. [Extracted from the article]

In a prospective observational study, two pediatric patients developed myocarditis after receiving the COVID-19 vaccine, elasomeran. The patients were hospitalized, but the outcomes were not specified. The study did not provide information on the ages, sexes, dosages, routes, or times to reaction onsets of the patients. [Extracted from the article]

A female patient developed myocarditis after receiving the COVID-19 mRNA vaccine during pregnancy. She presented with symptoms including chest pain, nausea, and elevated troponin levels. An echocardiogram showed reduced heart function. After a multidisciplinary assessment, an elective C-section was planned and performed without complications. The patient's myocarditis was attributed to the COVID-19 mRNA vaccine. [Extracted from the article]

A 72-year-old man developed chronic active lymphocytic myocarditis while being treated with pembrolizumab for supraglottic laryngeal squamous cell carcinoma. He also experienced a lack of efficacy when treated with prednisone for complete heart block. The man had pre-existing conditions including COPD, hypothyroidism, and metastatic lung disease. After presenting with shortness of breath, he was initially treated with steroids and discharged, but later experienced lethargy and heart block. He underwent pacemaker placement and was diagnosed with chronic active lymphocytic myocarditis, which was attributed to pembrolizumab therapy. Despite treatment with prednisone, the heart block persisted and he required a permanent pacemaker. [Extracted from the article]

A 79-year-old man developed myositis, myasthenia gravis (MG), and myocarditis (triple M syndrome) while being treated with pembrolizumab for stage IV nonsmall cell lung cancer. He experienced worsening dyspnea and physical examination revealed right ptosis. Further tests showed elevated troponin-I and creatine kinase levels, as well as ECG abnormalities. The patient was admitted to the ICU and received treatment for myocarditis and MG. He was discharged on a methylprednisolone taper and remained stable. The case was reported as an instance of pembrolizumab-induced triple M syndrome, which resulted in third-degree atrioventricular block, left bundle branch block, and complete heart block. [Extracted from the article]

A 16-year-old boy developed myocarditis after receiving the tozinameran COVID-19 vaccine. He experienced symptoms such as recurrent fever, chest pain, and shivering, and was admitted to the hospital. Tests showed elevated levels of troponin I and other markers of heart damage. The boy was treated with lisinopril and eventually made a full recovery with no residual abnormalities. [Extracted from the article]

A 75-year-old woman developed cardiogenic shock secondary to myocarditis while being treated with pembrolizumab for right upper extremity melanoma. Two weeks after starting pembrolizumab, she experienced symptoms such as dyspnea, cough, and decreased performance status. Her troponin I levels were elevated, and she was admitted to the emergency department. Despite not having obstructive coronary disease, her condition worsened, and she developed cardiogenic shock. Treatment with aspirin and high-dose methylprednisolone improved her condition. It was concluded that she developed pembrolizumab-induced myocarditis, which further complicated with multisystem organ failure and life-threatening cardiogenic shock. [Extracted from the article]

A 59-year-old woman developed myocarditis while undergoing treatment with camrelizumab for oesophageal cancer and hepatic metastases. The woman received camrelizumab in combination with paclitaxel and carboplatin for two cycles. During treatment, an electrocardiogram showed abnormal heart activity, and laboratory tests revealed abnormal levels of certain biomarkers. Despite the lack of symptoms, she was admitted to the hospital and diagnosed with camrelizumab-induced myocarditis. The woman was treated with immune-globulin and methylprednisolone, and her biomarkers eventually returned to normal. [Extracted from the article]

A 16-year-old boy developed myocarditis after receiving the tozinameran COVID-19 vaccine. He experienced symptoms such as recurrent fever, chest pain, and shivering, and was admitted to the hospital. Tests showed elevated levels of troponin I and other markers of heart damage. The boy was treated with lisinopril and eventually made a full recovery with no residual abnormalities. [Extracted from the article]

A 75-year-old woman developed cardiogenic shock secondary to myocarditis while being treated with pembrolizumab for right upper extremity melanoma. Two weeks after starting pembrolizumab, she experienced symptoms such as dyspnea, cough, and decreased performance status. Her troponin I levels were elevated, and she was admitted to the emergency department. Despite not having obstructive coronary disease, her condition worsened, and she developed cardiogenic shock. Treatment with aspirin and high-dose methylprednisolone improved her condition, but she experienced multisystem organ failure. It was concluded that she developed pembrolizumab-induced myocarditis, which further complicated with life-threatening cardiogenic shock. [Extracted from the article]

A 59-year-old woman developed myocarditis while undergoing treatment with camrelizumab for oesophageal cancer and hepatic metastases. The woman received camrelizumab in combination with paclitaxel and carboplatin for two cycles. An electrocardiogram showed abnormal results, and laboratory tests revealed abnormal levels of certain biomarkers. Despite the lack of symptoms, she was admitted to the hospital and diagnosed with camrelizumab-induced myocarditis. The woman was treated with immune-globulin and methylprednisolone, and her biomarkers eventually improved. [Extracted from the article]

A 13-year-old boy developed myocarditis after receiving the tozinameran (Pfizer-BioNTech COVID-19) vaccine. He experienced chest pain and shortness of breath within 20 hours of receiving the second dose. Tests showed elevated cardiac troponin levels and ST-segment elevation on his ECG. The boy was diagnosed with myocarditis secondary to the vaccine and was treated with ibuprofen. He recovered and had no symptoms during follow-up appointments. [Extracted from the article]

A 13-year-old boy developed myocarditis after receiving the tozinameran (Pfizer-BioNTech COVID-19) vaccine. He experienced chest pain and shortness of breath within 20 hours of receiving the second dose. Tests showed elevated cardiac troponin levels and ST-segment elevation on his ECG. The boy was diagnosed with myocarditis secondary to the vaccine and was treated with ibuprofen. He recovered and had no symptoms during follow-up appointments. [Extracted from the article]

A 78-year-old man with non-small cell lung cancer developed myocarditis while being treated with pembrolizumab. He also experienced fatigue and worsening kidney dysfunction during treatment with carboplatin, pemetrexed, and bevacizumab. After discontinuing the latter treatment and receiving betamethasone, he experienced severe fatigue and dyspnea on exertion, leading to a diagnosis of acute heart failure. The man was treated with ACE inhibitors and beta-blockers, and his symptoms improved. He was later diagnosed with myocarditis secondary to pembrolizumab and treated with prednisolone, which significantly reduced his symptoms. After reinitiating bevacizumab therapy, his cardiac function did not worsen and his overall condition improved. [Extracted from the article]

A 26-year-old woman developed acute myocarditis after receiving the BBIBP-CorV COVID-19 vaccine. She experienced flu-like symptoms, dyspnea, and rapidly progressive edema. Medical tests confirmed the diagnosis of acute myocarditis, and she was treated with medication for heart failure. After treatment, her symptoms improved, and her heart function returned to normal. [Extracted from the article]

A 46-year-old man experienced drug-induced diffuse myocarditis after intentionally overdosing on amlodipine. He presented to the emergency department with mild abdominal pain and was discharged the next day. However, he returned two days later with worsening dyspnea and was diagnosed with myocarditis based on symptoms and investigative findings. He was treated with furosemide and showed improvement in left ventricular function upon discharge. Three months later, a follow-up cardiac MRI showed significant improvement in myocardial inflammation. [Extracted from the article]

In a retrospective and observational study of 681 patients, two women developed myocarditis or pericarditis after receiving the tozinameran vaccine for COVID-19. The exact ages of the women were not provided, and details about the routes, dosages, and timing of the reactions were also not stated. One patient developed myocarditis, while the other developed pericarditis as a result of the tozinameran vaccine. [Extracted from the article]

A 62-year-old woman developed myocarditis with myositis/myasthenia gravis overlap syndrome while receiving treatment with pembrolizumab for endometrial adenocarcinoma. After her latest infusion, she experienced dyspnea, fatigue, and lower extremity edema. Laboratory tests indicated myocarditis, and she also exhibited neurological symptoms such as ptosis, dysarthria, and leg weakness. Treatment with steroids, plasma-exchange, and immune-globulin improved her neurological symptoms, but she later developed severe respiratory distress and required a tracheostomy and ventilation. [Extracted from the article]

A 75-year-old man developed myocarditis while being treated with pembrolizumab for metastatic prostate carcinoma and stage IVB adenocarcinoma of the left lung. He had a history of right bundle branch block and chronic pulmonary embolus. The patient received various treatments, including amiodarone, metoprolol, methylprednisolone, prednisone, colchicine, ibuprofen, and cotrimoxazole. His condition improved over time, with his troponin levels increasing during the tapering of prednisone but eventually returning to normal. After completing the prednisone taper, his left ventricular ejection fraction improved, suggesting subacute or chronic pericarditis. [Extracted from the article]

A 74-year-old man developed myocarditis while being treated with nivolumab for lung cancer. He presented with chest pain and was transferred to a cardiology center. Tests showed elevated levels of troponin-I, creatine kinase MB, brain natriuretic peptide, and C-reactive protein. Coronary angiography revealed a partial blockage in one of his arteries, and further imaging confirmed the presence of myocardial inflammation and microvascular obstruction. The man was diagnosed with nivolumab-induced myocarditis, but the outcome of his condition was not mentioned. [Extracted from the article]

A 58-year-old woman developed myocarditis while being treated with durvalumab for large cell neuroendocrine carcinoma of the lung. She also experienced lack of efficacy during treatment with methylprednisolone for myocarditis, as well as vasopressor and inotropic support for vasoplegic shock. The woman presented to the emergency department with altered mental status, hypotension, and fatigue. She was diagnosed with durvalumab-associated myocarditis and received treatment with methylprednisolone and abatacept. However, her condition worsened, leading to acute liver and renal failure, and she ultimately passed away. [Extracted from the article]

A 65-year-old woman with metastatic breast cancer developed acute myocarditis while being treated with gedatolisib. She had previously received chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel, but experienced lack of efficacy. Three days prior to presentation, she started taking gedatolisib and subsequently experienced tachycardia and dyspnea. Tests revealed ST elevation on ECG, elevated troponin levels, and findings consistent with acute myocarditis on cardiac imaging. The patient was discharged with a low dose of beta-blockers and plans for close follow-up. [Extracted from the article]

A 55-year-old woman developed acute lymphocytic myocarditis while being treated with lenalidomide for multiple myeloma. She was admitted to the emergency department with a heart attack and had a history of multiple myeloma and coronary artery disease. Tests showed abnormalities in her heart function and imaging confirmed myocarditis. She was treated with medication and discharged with partial recovery. [Extracted from the article]

A 54-year-old woman developed immune-mediated myocarditis while being treated with pembrolizumab for metastatic melanoma. Despite receiving treatment with mycophenolate-mofetil, immune-globulin, and unspecified corticosteroids, her condition worsened and she eventually died from immune-mediated myocarditis. The woman had initially been admitted to the hospital due to shortness of breath and elevated troponin levels. Cardiac imaging confirmed acute myocarditis, and the woman's abnormalities included atrioventricular block. The treatment she received was ineffective in preventing her death. [Extracted from the article]

A 62-year-old man developed eosinophilic myocarditis while being treated with dobutamine for cardiogenic shock. The man had a nonischaemic and biventricular heart failure and had previously experienced two episodes of cardiogenic shock within three months. He received dobutamine and epinephrine, and tests revealed low left ventricular ejection fraction, dilation of the heart chambers, and depressed right ventricular function. The man underwent a procedure to place an intra-aortic balloon pump and was given milrinone. However, he experienced RV failure and required a RV assist device. A biopsy showed acute eosinophilic myocarditis, which was believed to be caused by the dobutamine treatment. [Extracted from the article]

A case series describes two patients who developed autoimmune haemolytic anaemia (AIHA), myocarditis, and Evans syndrome while receiving treatment for stage IV melanoma metastases. The first patient, a 64-year-old woman, experienced lack of efficacy with multiple treatments and developed AIHA and Evans syndrome. The second patient, a 75-year-old man, developed AIHA and myocarditis. Both patients received treatment with prednisolone and experienced improvements in their conditions. However, the woman ultimately passed away, while the man continues to receive treatment in a clinical trial. [Extracted from the article]

A 37-year-old woman developed myocarditis after receiving the tozinameran COVID-19 vaccine. She had no previous cardiovascular disease but experienced symptoms such as fatigue, dyspnea, and peripheral edema. Tests showed left ventricular enlargement and dysfunction. The woman was treated with various medications and underwent MRI, which revealed improvement in her condition over a six-month follow-up period. [Extracted from the article]

A 60-year-old man developed fulminant myocarditis while being treated with pembrolizumab for renal cell carcinoma. He presented to the emergency department with chest pain and was diagnosed with ST-elevation myocardial infarction. Despite normal electrolyte levels and non-obstructive coronary artery disease, he remained hypotensive and required vasopressors. The diagnosis of pembrolizumab-induced fulminant myocarditis was made based on his symptoms and investigational findings. He was treated with high dose steroids, but his condition worsened and he ultimately passed away. [Extracted from the article]

A 66-year-old woman experienced acute encephalitis and myocarditis while being treated with pembrolizumab for endometrial carcinosarcoma. She had a history of hypertension and a previous cerebrovascular accident. During her hospital stay, she exhibited signs of myocarditis and developed acute encephalopathy. Treatment with high-dose methylprednisolone resulted in significant neurological and cardiac recovery. The adverse effects were attributed to pembrolizumab. [Extracted from the article]

Two case reports are described in this article, both involving patients who developed myocarditis while undergoing treatment for thymoma. The first patient, a 45-year-old man, experienced chest tightness, shortness of breath, and weakness after receiving sintilimab. Despite treatment with various medications, including immune-globulin and corticosteroids, he developed heart failure and ventricular arrhythmia and ultimately died. The second patient, a 58-year-old man, developed acute chest tightness and shortness of breath after receiving toripalimab. He was treated with corticosteroids and immune-globulin, and his condition improved. One year later, he showed stable disease. [Extracted from the article]

A 51-year-old woman developed acute eosinophilic myocarditis while being treated with mesalazine for Crohn's disease. She experienced symptoms such as chest pain, fever, and weakness, and her laboratory tests revealed elevated eosinophils and cardiac abnormalities. After further testing, she was diagnosed with acute eosinophilic myocarditis, which was believed to be caused by mesalazine. The woman was treated with steroids and her condition stabilized after stopping the medication. [Extracted from the article]

A 32-year-old man experienced acute myocarditis after receiving the influenza-virus-vaccine. He presented with chest pain, reduced exercise tolerance, and shortness of breath. His cardiac markers were elevated, and an EKG showed abnormalities. Treatment included aspirin and colchicine, and a cardiac MRI confirmed the diagnosis of myocarditis. The man was discharged with outpatient follow-up and advised to avoid strenuous activity. The article suggests a potential link between the influenza vaccine and acute myocarditis, but further research is needed to establish causation. [Extracted from the article]

A 26-year-old woman developed myocarditis while being treated with clozapine for bipolar I disorder with psychosis. She presented to the hospital with symptoms such as chills, dyspnea, and chest pain, along with tachycardia and elevated levels of troponin I and C-reactive protein. A cardiac magnetic resonance scan confirmed clozapine-induced myocarditis, and the woman was switched to lurasidone. Treatment with ibuprofen and colchicine led to symptom resolution in two weeks. [Extracted from the article]

A man in his 40s developed myocarditis after receiving the tozinameran (Pfizer BioNTech) COVID-19 vaccine. He experienced fever the day after vaccination and then suddenly lost consciousness and was admitted to the emergency department. Despite medical interventions, he suffered irreversible brain damage and multiple organ failure, leading to his death on the ninth day of admission. Autopsy results confirmed myocarditis as a result of the vaccine, and other contributing factors to his death included hypoxic encephalopathy, arrhythmia, and multiple organ failure. [Extracted from the article]

A 90-year-old woman with a history of breast cancer, pulmonary embolism, and coronary artery disease developed myocarditis and nephritis while being treated with pembrolizumab. She also developed adrenal insufficiency during treatment with prednisone. The woman presented with asymptomatic ventricular ectopy and atrial fibrillation and had elevated levels of brain natriuretic peptide, creatine kinase, and troponin T. Cardiac imaging confirmed the diagnosis of pembrolizumab-induced myocarditis. Treatment with high-dose prednisone improved her symptoms, but she developed adrenal insufficiency when the dose was tapered. Biopsy results confirmed nephritis secondary to pembrolizumab, and her cardiac biomarkers returned to normal after completing the prednisone taper. [Extracted from the article]

A 61-year-old woman developed myocarditis while being treated with pembrolizumab for non-small cell lung cancer. She presented with dyspnea and was found to have sinus tachycardia and elevated levels of NT-proBNP and troponin. An initial echocardiogram showed reduced left ventricular function, but subsequent tests showed improvement after treatment with methylprednisolone. The woman was discharged with a tapering dose of methylprednisolone. The myocarditis was determined to be associated with pembrolizumab. [Extracted from the article]

A 54-year-old man developed immune checkpoint-related myocarditis (ICIM) while being treated with pembrolizumab for acute myeloid leukemia. Three days after receiving pembrolizumab, he experienced ventricular tachycardia, severe chest pain, and shortness of breath. Diagnostic tests confirmed the presence of ICIM, and his treatment with pembrolizumab was discontinued. He was started on methylprednisolone and colchicine, and his symptoms resolved within three days. After eight weeks, his ICIM symptoms were completely resolved. [Extracted from the article]

A 75-year-old man developed myocarditis and myasthenia gravis while being treated with nivolumab for metastatic renal cell carcinoma. He experienced symptoms such as shortness of breath, fatigue, double vision, and difficulty swallowing. The man's vital signs indicated low blood pressure, rapid heart rate, and low oxygen levels. Laboratory tests revealed the presence of acetylcholine receptor antibodies and elevated troponin levels. Further investigations confirmed the diagnosis of nivolumab-induced myocarditis and myasthenia gravis. Despite treatment with steroids and plasmapheresis, the man experienced cardiac complications and died. [Extracted from the article]

A retrospective cohort study described 11 patients (8 men and 3 women) aged 22-57 years who developed myocarditis after receiving COVID-19 vaccinations. The patients received various vaccines, including AZD-1222, tozinameran, MVC-COV1901, and elasomeran. Symptoms included fever, palpitation, chest pain, and dizziness. Echocardiography and MRI showed abnormalities in left ventricular ejection fraction and cardiac troponin levels were elevated. Treatment with valsartan led to the recovery of left ventricular wall motion in one patient. Follow-up echocardiography showed improved left ventricular ejection fraction in six patients. [Extracted from the article]

A 65-year-old man developed myositis with myocarditis while being treated for metastatic renal cell carcinoma with ipilimumab and nivolumab. He also experienced lack of efficacy during treatment with immune-globulin and unspecified steroids for his condition. Despite receiving hydration, steroids, and IV immune-globulin, his symptoms worsened and he developed respiratory muscle weakness, tachyarrhythmias, and bradyarrhythmias. Unfortunately, he ultimately died due to myositis with myocarditis. [Extracted from the article]

A 29-year-old man developed myocarditis after abusing stanozolol and testosterone for muscular enhancement. He experienced chest and epigastric pain, dyspnea, and was found to be hypoxemic and tachycardic. Laboratory tests showed elevated troponin levels and a chest X-ray indicated pulmonary edema. A transthoracic echocardiogram revealed severe global hypokinesis of the left ventricle. The man admitted to taking stanozolol pills and receiving a testosterone injection. Treatment with methylprednisolone and prednisone improved his condition, and after four months, his chest pain resolved. [Extracted from the article]

A 42-year-old woman developed myocarditis after receiving pembrolizumab treatment for breast cancer. She experienced symptoms of heart failure, elevated troponin levels, and complete heart block. The woman was hospitalized and received temporary venous pacing. She was treated with steroids and her condition improved, with native conduction recovering and the pacing wire being removed. Cardiac MRI confirmed the diagnosis of pembrolizumab-induced myocarditis. The woman was discharged with a prolonged taper of oral steroids and close follow-up. [Extracted from the article]

A 65-year-old man developed myocarditis while being treated with pembrolizumab for metastatic small cell lung cancer. He presented with chest pain and further tests revealed abnormalities in his heart. It was determined that the myocarditis was a result of the pembrolizumab treatment. The man's treatment with pembrolizumab was discontinued and he responded well to steroid therapy. [Extracted from the article]

A 68-year-old man developed myocarditis while being treated with pembrolizumab for stage III lung adenocarcinoma. He experienced chest pain and shortness of breath and was hospitalized. Tests revealed severe biventricular dysfunction and intracardiac thrombi. The man received treatment with methylprednisolone, abatacept, and ruxolitinib, and his condition eventually improved. The myocarditis was confirmed to be a complication of pembrolizumab treatment. [Extracted from the article]

A 37-year-old woman developed autoimmune myocarditis and pneumonitis while undergoing treatment with pembrolizumab for stage 3 melanoma. She presented with symptoms such as chest pain, tachycardia, fatigue, dyspnea, and fever. Lab studies showed elevated troponin levels and CT scans revealed ground glass opacities in her lungs, indicating pembrolizumab-associated pneumonitis. Echocardiogram results showed a low left ventricular ejection fraction, indicating myocarditis. Despite a negative endomyocardial biopsy, the woman met diagnostic criteria for myocarditis based on elevated troponin levels and abnormalities on cardiac imaging. The autoimmune myocarditis led to heart failure, while the pneumonitis resulted in sepsis, disseminated intravascular coagulation, and respiratory failure. The woman's condition improved with treatment, including corticosteroids, and her left ventricular ejection fraction recovered. The article concludes that pembrolizumab was associated with the development of autoimmune myocarditis and pneumonitis in this case. [Extracted from the article]

An 82-year-old man developed fulminant myocarditis while being treated with nivolumab for oesophageal carcinoma. He presented with agonal breathing and altered mental status, and it was discovered that he had received his second dose of nivolumab therapy three days prior. The man experienced conduction system disease and high sensitivity troponin levels, leading to the diagnosis of nivolumab-induced fulminant myocarditis. He was treated with high-dose steroids and required a pacemaker for complete heart block. [Extracted from the article]

A 65-year-old man developed myocarditis and myositis while being treated with ipilimumab and nivolumab for metastatic renal cell carcinoma. Despite receiving treatment with immune-globulin, methylprednisolone, and mycophenolate, he experienced a lack of efficacy and his condition worsened. The man initially presented with weakness and was misdiagnosed with rhabdomyolysis. Laboratory tests revealed elevated levels of potassium, creatinine, and creatine phosphokinase. He was later diagnosed with myocarditis and myositis secondary to the medications. [Extracted from the article]

A 68-year-old woman with stage IV urothelial cancer developed complete heart block (CHB) and myocarditis while being treated with ipilimumab and nivolumab. She also experienced lack of efficacy with other medications for myocarditis. After receiving the dual immune checkpoint inhibitor therapy, the woman developed fulminant myocarditis with complete heart block, leading to acute hypoxic respiratory failure and the need for intubation. Despite aggressive treatment, her condition worsened and she eventually died. Autopsy findings confirmed severe myocarditis. The combination therapy was attributed to the development of CHB and myocarditis. [Extracted from the article]

A 66-year-old man developed lymphocytic myocarditis while being treated with ipilimumab and nivolumab for metastatic renal cell carcinoma. He experienced symptoms such as dizziness and diplopia, and was found to have high-grade atrioventricular block. Further investigations revealed elevated levels of troponin, transaminases, and creatinine kinase. Despite receiving a permanent pacemaker and showing improvement in his condition, the man later developed dysphagia, progressive weakness, and respiratory failure, leading to his death one month after the initial presentation. The article suggests a link between the use of ipilimumab and nivolumab and the development of lymphocytic myocarditis. [Extracted from the article]

A 27-year-old man experienced myocarditis after receiving the influenza-virus-vaccine. He presented with chest pain, sweating, nausea, and vomiting, and his troponin levels were elevated. Treatment included aspirin and heparin, followed by colchicine and aspirin. A cardiac MRI confirmed the diagnosis of myocarditis, which was believed to be a result of the vaccine. The man's symptoms improved with treatment and the myocarditis was resolving. [Extracted from the article]